N,N''-(methylenedi-4,1-phenylene)bis[N'-(4-methylphenyl)urea]

Endpoint summary

Description of key information

Acute oral (EU Method B.1): LD50 >2000 mg/kg bw

Acute dermal (OECD 402): LD50 >2000 mg/kg bw

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

February 1994 - March 1994

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

EU Method B.1 (Acute Toxicity (Oral))

Version / remarks:

december 1992

Deviations:

no

GLP compliance:

yes

Test type:

acute toxic class method

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

- Source: BRL Ltd., Basel, Switzerland.
- Age at study initiation: Young adult animals (approx. 9 weeks old)
- Weight at study initiation: Body weight variation was within +/- 20% of the sex mean (males 224 - 242 gram, females 171 - 188 gram).
- Fasting period before study: Food was withheld overnight prior to dosing until approximately 3-4 hours after administration of the test substance.
- Housing: Group housing of 3 animals per cage in labeled polycarbonate cages.
- Diet: Free access to pelleted rodent diet (Kliba 343 from KlingentalmOhle AG, Kaiseraugst, Switzerland).
- Water: Free access to tap water.
- Acclimation period: At least 5 days

ENVIRONMENTAL CONDITIONS
set to maintain:
- Temperature (°C): 21
- Humidity (%): 50
- Air changes (per hr): approx 15
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 17 February 1994 to 3 March 1994

Route of administration:

oral: gavage

Vehicle:

propylene glycol

Remarks:

adjusted for specific gravity: 1.036

Details on oral exposure:

Frequency: single dosage, on Day 1.

VEHICLE
- Justification for choice of vehicle: The vehicle was selected based on trial formulations performed at NOTOX and on test substance data supplied by the sponsor.

MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg bw

DOSAGE PREPARATION:
Formulation (w/w) was prepared immediately prior to dosing. The test substance was prepared in vehicle and adjustment was made for specific gravity of vehicle. Homogeneity was obtained by the use of a mechanical stirrer and electric blender.

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

10 (5 males and 5 females)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days

Frequency of observations and weighing:
- Mortality/Viability: Twice daily.
- Body weights: Days 1 (pre-administration), 8 and 15.
- Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15.
- Necropsy of survivors performed: Yes, all animals
- Other examinations performed: none.

Statistics:

No statistical analysis was performed (The method used is not intended to allow the calculation of a precise LD50 value).

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No animals died during the study .

Clinical signs:

Clinical signs observed in all animals on day 1 only, included lethargy and uncoordinated movements. One male also showed hunched posture on day 1.

Body weight:

The body weight gain shown by the animals over the study period was considered to be similar to that expected of normal untreated animals of the same age and strain.

Gross pathology:

Macroscopic post mortem examination of the animals at termination did not reveal any abnormalities.

Interpretation of results:

other: Not classified

Remarks:

According to Regulation (EC) No. 1272/2008 and its amendments.

Conclusions:

In an acute oral toxicity study with KY-AF in rats, performed according to EC test guidelines, an LD50 >2000 mg/kg bw was determined.

Executive summary:

An assessment of acute oral toxicity with KY-AF in the rat was performed according to EC test guideline and in accordance with GLP principles. KY-AF was administired by oral gavage to 5 male and 5 female Wistar rats at 2000 mg/kg bw. No mortality occured. Lethargy and uncoordinated movements were observed in all animals on day 1 and one male also showed hunched posture. The body weight gain shown by the animals over the study period was considered to be similar to that expected for normal untreated animals of the same age and strain. No abnormalities were found at macroscopic post mortem examination of the animals. The oral LD50 value of KY-AF in Wistar rats was established to exceed 2000 mg/kg body weight.

Based on these results, KY-AF does not have to be classified and has no obligatory labelling requirement for acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

The study has klimisch code 1.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Study period:

December 1999

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Version / remarks:

1987

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Version / remarks:

1992

Deviations:

no

GLP compliance:

yes

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

other: Wistar strain, Crl:WI (Han)

Sex:

male/female

Details on test animals or test system and environmental conditions:

- Source: Charles River Deutschland, Sulzfeld, Germany.
- Age at study initiation: Young adult animals (approx. 9 weeks old)
- Weight at study initiation: Body weight variation was within +/- 20% of the sex mean.
- Housing: Individually in labeled polycarbonate cages containing purified sawdust as bedding material.
- Diet: Free access to pelleted rodent diet (from Carfil Quality BVBA, Oud-Turnhout, Belgium).
- Water: Free access to tap water.
- Acclimation period: At least 5 days

ENVIRONMENTAL CONDITIONS
set to maintain:
- Temperature (°C): 21
- Humidity (%): 30 -70
- Air changes (per hr): approx 15
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 08 December 1999 to 22 December 1999

Type of coverage:

occlusive

Vehicle:

propylene glycol

Remarks:

Adjusted for specific gravity 1.036

Details on dermal exposure:

One day before exposure (Day -1) an area of approximately 5x7 cm on the back of the animal was clipped.

The formulation was applied in an area of approx. 10% of the total body surface, i.e. approx. 25 cm² for males and 18 cm² for females . The test substance was held in contact with the skin with a dressing, consisting of a surgical gauze patch, successively covered with aluminium foil and Coban flexible bandage . A piece of Micropore tape was additionally used for fixation of the bandages in females only .

Frequency: Single dosage, on Day 1.

Washing: Following application, dressings were removed and the skin cleaned of residual test substance using tap water.

Duration of exposure:

24 hours.

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

VEHICLE \\weglaten indien onverdund gedoseerd.
- Justification for choice of vehicle: The vehicle was selected based on trial formulations performed at NOTOX and on test substance data supplied by the sponsor.

Dose volume: 10 mL/kg

DOSAGE PREPARATION:
The formulation (w/w) was prepared within 4 hours prior to dosing. Homogeneity was accomplished to a visually acceptable level . Adjustment was made for specific gravity of vehicle.

Duration of observation period following administration: 14 days
Frequency of observations and weighing:
- Mortality/Viability: Twice daily.
- Body weights: Days 1 (pre-administration}, 8 and 15 .
- Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15.
- Necropsy of survivors performed: Yes, all animals
- Other examinations performed: none.

Statistics:

No statistical analysis was performed .

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No mortality occurred.

Clinical signs:

No clinical signs of systemic toxicity were observed in any of the animals.

Body weight:

The changes noted in body weight gain in males and females were within the range expected for rats used in this type of study and were therefore considered not indicative of toxicity.

Gross pathology:

No abnormalities were found at macroscopic post mortem examination of the animals.

Other findings:

Erythema was seen in the treated skin-area of one of the females on day 6 only .

Interpretation of results:

other: Not classified.

Remarks:

According to Regulation (EC) No. 1272/2008 and its amendments.

Conclusions:

In an acute dermal toxicity study with rats, performed according to EC test guidelines, an LD50 >2000 mg/kg bw was determined.

Executive summary:

An assessment of acute dermal toxicity with KY-AF in the rat was performed according to EC test guideline and in accordance with GLP principles. KY-AF was administired by dermal application to 5 male and 5 female Wistar rats at 2000 mg/kg bw for 24 hours. No mortality occured and no clinical signs of systemic toxicity were observed in any of the animals. Erythema was seen in the treated skin-area of one of the females on day 6 only . The body weight gain shown by the animals over the study period was considered to be similar to that expected for normal untreated animals of the same age and strain. No abnormalities were found at macroscopic post mortem examination of the animals. The dermal LD50 value of KY-AF in Wistar rats was established to exceed 2000 mg/kg body weight.

Based on these results, KY-AF does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

The study has klimisch code 1.

Additional information

Acute oral:

An assessment of acute oral toxicity with KY-AF in the rat was performed according to EC test guideline and in accordance with GLP principles. KY-AF was administered by oral gavage to 5 male and 5 female Wistar rats at 2000 mg/kg bw. No mortality occurred. Lethargy and uncoordinated movements were observed in all animals on day 1 and one male also showed hunched posture. The body weight gain shown by the animals over the study period was considered to be similar to that expected for normal untreated animals of the same age and strain. No abnormalities were found at macroscopic post mortem examination of the animals. The oral LD50 value of KY-AF in Wistar rats was established to exceed 2000 mg/kg body weight.

Acute dermal:

An assessment of acute dermal toxicity with KY-AF in the rat was performed according to EC test guideline and in accordance with GLP principles. KY-AF was administered by dermal application to 5 male and 5 female Wistar rats at 2000 mg/kg bw for 24 hours. No mortality occurred and no clinical signs of systemic toxicity were observed in any of the animals. Erythema was seen in the treated skin-area of one of the females on day 6 only. The body weight gain shown by the animals over the study period was considered to be similar to that expected for normal untreated animals of the same age and strain. No abnormalities were found at macroscopic post mortem examination of the animals. The dermal LD50 value of KY-AF in Wistar rats was established to exceed 2000 mg/kg body weight.

Justification for classification or non-classification

Based on the available study results, KY-AF does not have to be classified and has no obligatory labelling requirement for acute oral and acute dermal toxicity according to Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures (including all amendments).